ArticleFrontiers in public health2025
Global burden of tracheal, bronchus, and lung cancer attributable to second-hand smoke exposure from 1992 to 2021: an age-period-cohort analysis and 25-year mortality projections.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tracheal, bronchus, and lung (TBL) cancer remains the leading cause of cancer-related mortality worldwide. While smoking is the primary risk factor, several non-smoking-related factors also significantly contribute to TBL cancer, notably second-hand smoke (SHS) exposure, which plays a substantial role in the disease's burden. This study assesses and forecasts the temporal trends in the disease burden of TBL cancer attributable to SHS exposure at global, regional, and national levels. Methods: We extracted data from the ≥ 25 years population in the Global Burden of Disease Study 2021 (GBD 2021) to assess deaths, disability-adjusted life years (DALYs), age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR) at both global and regional levels. We evaluated temporal trends using descriptive statistics, estimated annual percentage change (EAPC), and both the age-period-cohort (APC) and Bayesian age-period-cohort (BAPC) models. Results: From 1992 to 2021, absolute deaths and DALYs linked to TBL cancer due to SHS exposure increased, although ASMR and ASDR showed declining trends, with EAPC values of -0.92% and -1.30%, respectively. Regions with a high socio-demographic index (SDI) displayed the most significant improvements. In contrast, high-middle and middle SDI regions bore the greatest disease burden, and low SDI regions saw minimal progress. The highest ASMR in 2021 occurred mainly in Western Europe, North America, and East Asia, with ASMR correlating positively with SDI. The disease burden was consistently higher among males, particularly in the 65-74 age group, across both sexes. Future projections indicate a continuing decline in the disease burden from 2022 to 2046. Conclusion: SHS exposure continues to be a significant factor in the disease burden of TBL cancer. Although there has been an overall declining trend globally, it still caused the deaths of more than 97,000 people in 2021. There exists considerable heterogeneity among regions, with some areas still bearing a substantial disease burden. These findings highlight the need for specific prevention and control strategies to mitigate the health impacts of SHS exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.